Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
06678 百德醫療
Listing Date2022/10/05    Suspended
Listing Price1.400

Betters Medical Investment Holdings is one of the leading microwave ablation (MWA) medical device developers and providers in the PRC for minimally invasive treatment of tumours. Its proprietary MWA medical devices are used for treatment of benign and malignant tumours including thyroid nodules, liver cancer, lung cancer and breast lumps. Its pipeline products mainly consist of MWA therapeutic apparatus as well as MWA needles that are used in conjunction with the therapeutic apparatus.

According to Frost & Sullivan, the Group ranked first among MWA medical device providers in the treatment for thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of MWA needles in 2021. Further, it was the third largest MWA medical device provider in the PRC in terms of sales revenue in 2021.

The Group is the first company to have proprietary MWA medical devices specifically indicated for thyroid nodules registered as Class III medical devices. It possessed a total of 27 registered patents and 20 patents under application.

Its products are ultimately sold to hospitals were mostly Grade II and Grade III hospitals. For 5M2022, 259 hospitals in China procured its products, among which, 150 were Grade IIIA hospitals.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot2000
No. of Offer Shares248.00M shares
No. of International Offer Shares202.92M shares
No. of HK Offer Shares45.08M shares
Offer Price$1.40 - $1.72
Stock Code6678
Sponsor(s)BOCI Asia Limited, Zhongtai International Capital Limited
Underwriter(s)BOCI Asia Limited, Zhongtai International Securities Limited, China Galaxy International Securities (Hong Kong) Co., Limited, Cinda International Capital Limited, Huatai Financial Holdings (Hong Kong) Limited, Eddid Securities and Futures Limited, China Everbright Securities (HK) Limited, Guosen Securities (HK) Capital Company Limited, China Industrial Securities International Capital Limited, Valuable Capital Limited, ZMF Asset Management Limited
Application PeriodSep 22 (Thu) - noon, Sep 27 (Tue)
Price Determination DateSep 27 (Tue)
Result Announcement DateOn or before Oct 03 (Mon)
Result Announcement DateOn or before Oct 03 (Mon)
Dealings in Shares commence onOct 05, 2022. (Wed)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$1.40 - $1.72
Capitalization2.24B - 2.75B
NAV / share ($)$0.29 - $0.34 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 1.56, the net proceeds raised would be HKD 300.20M, of which
41% : Broadening and deepening product portfolio, upgrading medical licences and expanding R&D team
38% : Pursuing strategic acquisitions, investment or synergistic business cooperation
8% : Expanding its presence in foreign and emerging markets by setting up overseas offices
3% : Acquiring automated machineries and equipment to improve the automation level of production lines
10% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.